ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Mild Photothermal Bimetallic Mesoporous Nanozyme Triggers Immunogenic Cell Death and Immune Contexture Remodeling for Precision Hepatocellular Carcinoma Treatment.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A biomimetic magnetic MOF-based nanoplatform for HMaterials today. Bio · 2026Article
- Biomimetic PD-1-nanovesicles inducing tri-modal sonodynamic-chemo-immunotherapy for breast cancer therapy and lung metastasis inhibition.Journal of nanobiotechnology · 2026Article
- Precise Catalysis and Immune Activation: New Strategies for Tumor Immunotherapy with Cascade Nanozymes.International journal of nanomedicine · 2026Review
- Mild Photothermal Bimetallic Mesoporous Nanozyme Triggers Immunogenic Cell Death and Immune Contexture Remodeling for Precision Hepatocellular Carcinoma Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Treating hepatocellular carcinoma (HCC) remains a significant clinical challenge because of its immunosuppressive tumor microenvironment (TME) and poor response to immunotherapy. Immunogenic cell death (ICD) has emerged as a promising strategy for enhancing antitumor immunity through the release of tumor-associated antigens (TAAs) and damage-associated molecular patterns (DAMPs). However, efficient ICD induction requires precise regulation of oxidative stress, which is hindered by the robust antioxidant defenses of tumors, particularly glutathione (GSH)-mediated reactive oxygen species (ROS) scavenging. To address this, a platinum-cobalt (Pt/Co) bimetallic nanozyme (BNzyme) with a mesoporous structure is developed, which exhibited enzymatic activities similar to those of peroxidase (POD) and glutathione peroxidase (GPx). The Pt/Co BNzyme not only catalyzed H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.